文献速递创伤与烧伤

创伤性动脉损伤自体静脉与合成移植物间置术的院内结局:PROOVIT倾向匹配队列

In-hospital outcomes in autogenous vein versus synthetic graft interposition for traumatic arterial injury: A propensity-matched cohort from PROOVIT.
PubMed 文献 · J Trauma Acute Care Surg · 2022-01-01
一句话结论PROOVIT倾向匹配队列显示,创伤性动脉损伤使用合成移植物者病情更重,但匹配后自体静脉与合成移植物在院内再手术或血管内干预率无差异(18%;p=0.8)。

该研究基于美国创伤外科协会PROOVIT前瞻性观察性血管损伤治疗登记库(2013年11月至2019年1月),纳入需间置静脉或移植物修复的动脉损伤患者,排除无损伤严重度评分记录者,其他缺失数据采用多重插补。共识别来自19家机构的460例患者,其中402例接受静脉移植物(VG),58例接受合成移植物(SG;45例PTFE、5例Dacron、8例其他导管)。SG组入院时伤情更重,枪伤更多,平均损伤严重度评分、乳酸和最初24小时输血需求更高,入院收缩压、pH和血红蛋白显著更低。倾向匹配后51例SG与87例VG匹配,匹配后两组人口学、临床参数或诊断评估技术无差异;主要终点再手术或血管内干预需求相当(18%;p=0.8),包括血栓形成、狭窄、假性动脉瘤、感染或栓塞事件在内的任何次要结局均无差异,住院和重症监护室停留时间相同。结论认为,控制相关临床因素和倾向匹配后,VG与SG在院内再手术或血管内干预率或任何次要结局方面无差异。

要点

  • 倾向匹配后,合成移植物组与静脉移植物组的院内再手术或血管内干预率相当(18%;p=0.8)。
  • 匹配后两组在血栓形成、狭窄、假性动脉瘤、感染或栓塞事件等任何次要结局上均无差异,住院和ICU停留时间相同。
  • 匹配前合成移植物组伤情更重:枪伤更多,平均损伤严重度评分、乳酸和最初24小时输血需求更高,入院收缩压、pH和血红蛋白显著更低。
  • 合成移植物组58例中45例为PTFE、5例为Dacron、8例为其他导管;静脉移植物组402例。
  • 证据等级为预后与流行病学Level III。

适用人群与场景

  • 美国创伤外科协会PROOVIT前瞻性观察性血管损伤治疗登记库(2013年11月至2019年1月)中需要间置静脉或移植物修复的动脉损伤患者。
  • 排除无损伤严重度评分记录的患者;其他缺失数据采用多重插补。

研究设计与关键结果

  • 研究类型为倾向匹配队列,来自19家机构,共识别460例患者,其中402例接受静脉移植物(VG),58例接受合成移植物(SG);SG组中45例为PTFE、5例为Dacron、8例为其他导管。
  • 匹配前SG组入院时伤情更重:枪伤更多,平均损伤严重度评分、乳酸和最初24小时输血需求更高,入院收缩压、pH和血红蛋白显著更低。
  • 倾向匹配后51例SG与87例VG匹配,匹配后两组人口学、临床参数或诊断评估技术无差异。
  • 匹配后主要终点再手术或血管内干预需求相当(18%;p=0.8)。
  • 匹配后任何次要结局(血栓形成、狭窄、假性动脉瘤、感染或栓塞事件)均无差异,住院和ICU停留时间相同。

证据类型、等级与局限

  • 证据类型:基于前瞻性观察性登记库的倾向匹配队列研究;证据等级:预后与流行病学Level III。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在控制相关临床因素和倾向匹配后,静脉移植物与合成移植物在院内再手术或血管内干预率或任何次要结局方面无差异。
  • 登记库数据显示合成移植物用于更危重的患者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The ideal conduit for traumatic arterial repair is controversial. Autologous vein was compared with synthetic interposition grafts in the acute setting. The primary outcome was in-hospital reoperation or endovascular intervention.

METHODS: The American Association for the Surgery of Trauma PROspective Observational Vascular Injury Treatment registry from November 2013 to January 2019 was queried for arterial injuries requiring interposition vein or graft repair. Patients with no recorded Injury Severity Score were excluded, and multiple imputation was used for other missing data. Patients treated with synthetic grafts (SGs) were propensity matched to patients with vein grafts (VGs) to account for preoperative differences.

RESULTS: Four hundred sixty from 19 institutions were identified, with 402 undergoing VG and 58 SG. In the SG group, 45 were PTFE grafts, 5 were Dacron, and 8 had other conduits. The SG group was more severely injured at admission with more gunshot wounds and higher mean Injury Severity Score, lactate, and first-24-hour transfusion requirement. In addition, the SG cohort had significantly lower admission systolic blood pressure, pH, and hemoglobin. After propensity matching, 51 patients with SG were matched with 87 patients with VG. There were no differences in demographics, clinical parameters, or diagnostic evaluation techniques postmatch. The need for reoperation or endovascular intervention between the matched groups was equivalent (18%; p = 0.8). There was no difference in any secondary outcome including thrombosis, stenosis, pseudoaneurysm, infection, or embolic event, and hospital and intensive care unit length of stay were the same.

CONCLUSION: American Association for the Surgery of Trauma PROspective Observational Vascular Injury Treatment registry data demonstrate that SGs are used in more critically ill patients. After controlling for relevant clinical factors and propensity matching, there is no in-hospital difference in rate of reoperation or endovascular intervention, or any secondary outcome between VG and SG.

LEVEL OF EVIDENCE: Prognostic and Epidemiolgic, Level III.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Stonko DP, Betzold RD, Abdou H, et al. In-hospital outcomes in autogenous vein versus synthetic graft interposition for traumatic arterial injury: A propensity-matched cohort from PROOVIT. J Trauma Acute Care Surg. 2022. PMID: 34789705. doi:10.1097/TA.0000000000003465

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。